111 related articles for article (PubMed ID: 32361056)
21. Phosphorylation of eIF2α suppresses cisplatin-induced A549 cell apoptosis via p38 inhibition.
Guo L; Chen R; Ma N; Xiao H; Chen Y; Chen F; Mei J; Ding F; Zhong H
Cancer Biother Radiopharm; 2013 May; 28(4):268-73. PubMed ID: 23570372
[TBL] [Abstract][Full Text] [Related]
22. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
23. Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.
Zhang T; Ma L; Wu P; Li W; Li T; Gu R; Dan X; Li Z; Fan X; Xiao Z
Oncol Rep; 2019 Mar; 41(3):1779-1788. PubMed ID: 30747218
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
27. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.
Lee MW; Kim DS; Min NY; Kim HT
Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
29. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation.
Xin M; Deng X
J Biol Chem; 2006 Jul; 281(27):18859-67. PubMed ID: 16679323
[TBL] [Abstract][Full Text] [Related]
30. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
[TBL] [Abstract][Full Text] [Related]
31. Microcystin-LR induces a wide variety of biochemical changes in the A549 human non-small cell lung cancer cell line: Roles for protein phosphatase 2A and its substrates.
Wang H; Xu K; Wang B; Liu J; Wang X; Xing M; Huang P; Guo Z; Xu L
Environ Toxicol; 2017 Mar; 32(3):1065-1078. PubMed ID: 27352821
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
33. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
[TBL] [Abstract][Full Text] [Related]
34. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
35. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
36.
Seo SH; Kim SG; Shin JH; Ham DW; Shin EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927892
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase.
Boudreau RT; Conrad DM; Hoskin DW
Cell Signal; 2007 Jan; 19(1):139-51. PubMed ID: 16844342
[TBL] [Abstract][Full Text] [Related]
38. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
39. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
[TBL] [Abstract][Full Text] [Related]
40. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
